Get the Stockscreener App
12.12
2.97%
0.35
Cogent Biosciences Inc stock is traded at $12.12, with a volume of 1.15M.
It is up +2.97% in the last 24 hours and down -2.65% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$11.77
Open:
$11.91
24h Volume:
1.15M
Relative Volume:
0.42
Market Cap:
$1.38B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-6.809
EPS:
-1.78
Net Cash Flow:
$-234.65M
1W Performance:
+1.93%
1M Performance:
-2.65%
6M Performance:
+51.50%
1Y Performance:
+24.69%
1-Day Range:
$11.81
$12.44
1-Week Range:
$11.53
$12.44
52-Week Range:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.12 | 1.69B | 0 | -284.08M | -234.65M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences Inc. Inches Above Key Support — Safe to HoldIndex Update & Daily Growth Stock Investment Tips - thegnnews.com
Cogent Biosciences, Inc. $COGT Stock Position Lessened by XTX Topco Ltd - MarketBeat
Cogent Biosciences Inc. Price Targets Raised After ReboundJuly 2025 Technicals & Risk Controlled Swing Alerts - kangso.co.kr
Is Cogent Biosciences Inc. a good ESG investment2025 Volatility Report & Community Driven Trade Alerts - thegnnews.com
What makes Cogent Biosciences Inc. stock price move sharplyJuly 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Backtesting results for Cogent Biosciences Inc. trading strategiesRisk Management & Real-Time Buy Signal Alerts - Newser
Can volume confirm reversal in Cogent Biosciences Inc.Weekly Trade Review & Long-Term Safe Investment Plans - Newser
Live market analysis of Cogent Biosciences Inc.2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
Can technical indicators confirm Cogent Biosciences Inc.’s reversalJuly 2025 Action & Community Consensus Stock Picks - Newser
What machine learning models say about Cogent Biosciences Inc.2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Cogent Biosciences Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
When is the best time to buy Cogent Biosciences Inc. stockEarnings Overview Report & Safe Entry Point Identification - Newser
Real time breakdown of Cogent Biosciences Inc. stock performanceJuly 2025 Drop Watch & Daily Profit Maximizing Trade Tips - Newser
Is There Enough Volume to Lift Cogent Biosciences Inc.Rate Hike & Daily Chart Pattern Signal Reports - sundaytimes.kr
XTX Topco Ltd Cuts Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Using data filters to optimize entry into Cogent Biosciences Inc.2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
Knott David M Jr Takes $1.28 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Drawdown in Cogent Biosciences Inc. May Be Nearing EndTrade Exit Summary & Daily Oversold Stock Bounce Ideas - kangso.co.kr
Do Rising R&D Losses at Cogent Biosciences (COGT) Reflect Strategic Vision or Escalating Risk? - simplywall.st
Resistance Break Could Fuel Cogent Biosciences Inc. Rally2025 Top Decliners & Verified Chart Pattern Trade Signals - beatles.ru
Wedbush Lowers Earnings Estimates for Cogent Biosciences - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of COGT Q3 Earnings - MarketBeat
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - The Globe and Mail
Cogent Biosciences Reports First Quarter 2025 Financial Results - The Globe and Mail
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Globe and Mail
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - The Globe and Mail
Cogent Biosciences to Participate in the Guggenheim Biotech Conference - The Globe and Mail
Q3 EPS Forecast for Cogent Biosciences Raised by Analyst - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cogent Biosciences (NASDAQ:COGT) Stock - MarketBeat
Wedbush Reduces Earnings Estimates for Cogent Biosciences - MarketBeat
Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright - MSN
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $30.00 - Defense World
HC Wainwright Issues Pessimistic Forecast for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
How Investors Are Reacting To Cogent Biosciences (COGT) Widening Losses in Q2 and First Half 2025 - simplywall.st
Leerink Partnrs Issues Negative Outlook for COGT Earnings - Defense World
Cogent Biosciences shares fall 1.64% intraday after Cogent Communications misses Q2 net loss per share estimates. - AInvest
Cogent Biosciences Reports Increased Losses Amidst Ongoing Development - The Globe and Mail
Cogent Biosciences Reports Positive Trial Results, Updates Financial Position - AInvest
Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating - 富途牛牛
COGT Stock Rating Maintained by HC Wainwright, Price Target Lowe - GuruFocus
Cogent Biosciences (COGT) Price Target Revised by Analyst - GuruFocus
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences - TipRanks
Cogent Biosciences: KDJ Golden Cross and Bullish Marubozu Indicators Detected - AInvest
Cogent Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cogent Biosciences Reports Recent Business Highlights and Secon - GuruFocus
Cogent Biosciences' Q2 net loss widens as costs mount - TradingView
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewswire
BRIEF-Cogent Biosciences Q2 Operating Expenses USD 75.581 Million - TradingView
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cogent Biosciences Inc Stock (COGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinnow Cole | Chief Commercial Officer |
Jan 14 '25 |
Buy |
7.60 |
43,750 |
332,412 |
45,848 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):